Roche Reports Interim Phase III Sefaxersen Data in IgA Nephropathy

Roche said interim data from the ongoing Phase III IMAgINATION study showed investigational sefaxersen significantly reduced proteinuria in adults with primary IgA nephropathy receiving optimized standard of care.